[Imc-germany] Check out this short news clip on MGRM
ronraphael at gmail.com
Mo Jul 9 12:22:27 PDT 2007
wow great video from the very much respected San Francisco Bay Area T.V.
station on MGRM and did you see how clean the MGRM Laboratory was? looks
like a well run Company no wonder Pfizer, Mreck, Shering and European
Pharama Companies Respect and Rely on MGRM HIV Troflie testing and I can see
why the FDA respected the highly professional staff at MGRM and the data
from MGRM and Pfizer during Clincal trials on Maraviroc/Celsentri HIV drug
and with such accurate and trustworthy data the FDA was able to recommend
unanimously 12-0 for fast track approval for Maraviroc/Celsentri.
I suspect we shall all see soon the labeling issue on Pfizer & FDA concluded
anyday now maybe even today and Maraviroc/Celsentri HIV drug along with MGRM
Trofile test will then be Marketed World Wide by Pfizer as planned.
Thanks nettripper2002 for posting this fantastic link. Broadcast states the
price for the trofile test is $1500.
40,000 possible candidates for Maraviroc in the US alone gives us enough
revenue for an easy double. (40000 x 1500 = 60,000,000 in revenues.) And if
PFE can get the FDA to broaden the Maraviroc label the uptake could be much
I really liked the last line of the report
"It sounds like it's expensive but I guess if it saves your life it's well
worth it. Not only that Insurance companies will pay for it because they
found that by avoiding even one month of very expensive medication it's well
worth the $1500 cost."
*Check out this short news clip on MGRM* -
I stumbled across this video this early a.m. and was fascinated by it and
wanted to share it with the rest of you MGRM'ers.
I may not be as astute as you in detail, however, I intuitively caught the
enthusiasm radiating on William Young's face when he spoke.
i.e. (non-verbal communication.)
As you are well aware of companies cannot disclose every aspect of their
Young gave his vote of confidence in that clip.
SOUTH SAN FRANCISCO, Calif., June 25 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM <http://finance.yahoo.com/q?s=mgrm&d=t> -
News <http://finance.yahoo.com/q/h?s=mgrm>) announced today that William D.
Young, CEO and Chairman, is scheduled to present a corporate overview at the
C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on
Wednesday, July 11, 2007 at 3:00 p.m. (Eastern Time) at the Mandarin
Oriental Hotel in New York City, New York.
To access the live audio broadcast or the subsequent archived recording, log
on to http://www.monogrambio.com and go to the investor relations section
("Investors/Media" tab) and click on the "Events & Webcasts" link provided
on the sidebar menu on the page.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and
marketing innovative products to guide and improve treatment of serious
infectious diseases and cancer. The Company's products are designed to help
doctors optimize treatment regimens for their patients that lead to better
outcomes and reduced costs. The Company's technology is also being used by
numerous biopharmaceutical companies to develop new and improved antiviral
therapeutics and vaccines as well as targeted cancer therapeutics. More
information about the Company and its technology can be found on its web
site at http://www.monogrambio.com.
PFE Monogram's collaborator, Pfizer Inc meeting is on the 18th ..said it has
received an approvable letter from the FDA for maraviroc, a CCR5-antagonist
under review as a therapy for treatment-experienced patients infected with
CCR5-tropic HIV-1. The Trofile assay was used to select the more than 2,000
patients worldwide who have received treatment with maraviroc through
clinical trials, the South San Francisco, Calif.-based biotechnology company
said. Trofile is currently in use for patient selection in Pfizer's ongoing
expanded access program, the company noted.
One trend called "personalized medicine" will change medicine. Major
drug companies are using personalized tests to develop new and better
medicine - medicine that will target diseases that are specific to
individual patients. It's only a matter of time before the entire medical
world is catering to your specific ailments.
This tiny company's patented testing solutions enable doctors to tailor
their treatments to the precise needs of each patient. In fact, this "next
generation" of medical tests has proven to be close to 100% accurate. The
best any of Daily's mentioned less-advanced mainstream tests could get was a
65% accuracy rate.
That's why this $220 million company will soon emerge as a leader in
personalized medicine. And it's also why doctors around the world will trust
this company's tests to help them treat their patients.
With the technology to make personalized medicine mainstream, this company
will not be trading at $1.68 a share for too much longer.
Right now, some of the biggest and most cutting-edge drug companies in the
world are using sophisticated new tests. These tests help to better select
patients for clinical trials for new HIV and cancer treatments. And soon,
physicians across the globe will be using these same techniques to treat
patients will all sorts of diseases. Not just HIV.
The developer of these diagnostic tests isn't Merck or Pfizer. Instead, it's
a small $220 million firm. This one small company has partnered with more
than 60 pharmaceutical, biotech and research organizations. This includes
almost every company with a significant HIV drug development program.
The bottom line is that any company that wants to gain a foothold in HIV
treatments needs this unknown company to survive.
This drug company savior is Monogram Biosciences, Inc. MGRM: NASDAQ). The
company develops special testing products that are so accurate that the big
pharmaceutical companies are using the technology to develop better
It's all part of the new personalized medicine trend. As technology
improves, it is becoming possible for doctors and drug companies to diagnose
exactly what strain of the disease patients have. From there, physicians can
better treat their patients using very specific drugs.
But it's not just a simple HIV test that makes Monogram such an important
company. Twenty years ago, all HIV-positive patients were treated the same
and had short life expectancies. But now, treatments are getting far more
advanced. We're seeing those who suffer from the virus living longer lives.
Unfortunately, with more advanced treatments comes a disease that has begun
to mutate and become even more deadly.
You see, different strains and mutations of HIV exist. That's what makes
viruses so deadly. They can adapt to work around the current treatments that
are widely used today.
This is why Monogram's tests are important. This company's unique tests tell
physicians and drug companies what specific viruses a patient has in his
body and how the viruses are spreading through his system. Once they have
this information, doctors can prescribe specific drugs that help target the
specific virus strains and block how the disease infects healthy cells.
As these specialty drugs are developed, doctors across the globe will rely
on these tests to tell them if the drugs will work for their patients.
Including those with the most deadly diseases known to man.
-------------- nächster Teil --------------
Ein Dateianhang mit HTML-Daten wurde abgetrennt...